2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
6874
Lung Neoplasms
5105
Small Cell Lung Carcinoma
1166
Breast Neoplasms
855
Neoplasms
762
Colorectal Neoplasms
670
Melanoma
566
Ovarian Neoplasms
506
Neoplasm Metastasis
481
Pancreatic Neoplasms
473
Adenocarcinoma of Lung
398
Stomach Neoplasms
396
Prostatic Neoplasms
370
Head and Neck Neoplasms
368
Carcinoma, Renal Cell
350
Esophageal Neoplasms
337
Squamous Cell Carcinoma of Head and Neck
325
Mesothelioma, Malignant
324
Colonic Neoplasms
294
Mesothelioma
289
Urinary Bladder Neoplasms
262
Brain Neoplasms
254
Uterine Cervical Neoplasms
243
Triple Negative Breast Neoplasms
223
Sarcoma
198
Endometrial Neoplasms
196
Carcinoma, Hepatocellular
186
NSCLC
167
Pleural Effusion, Malignant
160
Kidney Neoplasms
160
Interventions
dalotuzumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Insulin-Like Growth Factor I, Resistance To
×
Thoracic
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled